Mitra RxDx (dba Mitra Biotech) is a Boston, MA-based company founded in 2010 that develops tools to advance personalized oncology treatment. Its core product is the CANscript™ platform, which delivers individualized treatment response predictions with high correlation to clinical outcomes to inform patient-specific cancer treatment selection and support efficient cancer drug development. The company maintains a research and laboratory presence in Bengaluru, India. Mitra completed a $40M financing that brings cumulative funding to date to $76M. It plans to use the funds to expand commercial efforts and continue building clinical evidence to accelerate adoption and secure reimbursement in the U.S. and other key markets. Leadership includes founder Mallikarjun Sundaram, President and CEO.

Total raised

$40M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2018